ModerateSelective COX-2 inhibitor (coxib)×X-ray contrast media. Watersoluble nephrotropic low-osmolar iodinated agents
Updated · Methodology
Mechanism
After intra-arterial or intravenous use, iopromide can cause acute kidney injury, usually a transient fall in renal function and sometimes acute renal failure (iopromide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The risk is higher with pre-existing renal impairment, dehydration, diabetes mellitus, multiple myeloma and large or repeated doses of contrast (AEMPS). The US iopromide label also lists concomitant nephrotoxic or diuretic drugs among the risk factors (iopromide label, US Food and Drug Administration, FDA). Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID). When renal perfusion is compromised, it can reduce renal prostaglandin formation and, as a result, renal blood flow and renal function (etoricoxib SmPC, AEMPS). The documents do not address iopromide with etoricoxib or with other NSAIDs directly.
Symptoms
After contrast, renal function may fall temporarily, and acute renal failure sometimes develops (iopromide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). This usually shows only as a rise in blood creatinine. With etoricoxib, proteinuria, raised serum creatinine and renal failure are uncommon. Fluid retention, oedema and high blood pressure have been seen in people taking it (etoricoxib SmPC, AEMPS).
Management
The documents do not prohibit the combination and do not address it directly. Ensure adequate hydration in all patients before intra-arterial or intravenous iopromide, especially in people with diabetes mellitus, multiple myeloma or renal impairment and in older people (iopromide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Prophylactic intravenous hydration is not recommended at an estimated glomerular filtration rate (eGFR) of 30–59 mL/min/1.73 m², because no added renal benefit has been shown. At eGFR below 30 mL/min/1.73 m² with heart disease, it may increase serious cardiac complications (AEMPS). The US label says to hydrate patients before and after iopromide and to use the lowest necessary dose in renal impairment. It also says not to use laxatives, diuretics or preparatory dehydration before the procedure (iopromide label, US Food and Drug Administration, FDA). Etoricoxib is contraindicated at creatinine clearance below 30 mL/min. In pre-existing renal impairment, uncompensated heart failure or cirrhosis, consider monitoring renal function (etoricoxib SmPC, AEMPS). Start etoricoxib with caution in dehydrated patients. Rehydrating them before treatment is advisable (AEMPS). If renal function worsens during treatment, take appropriate measures and consider stopping etoricoxib (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Ultravist 370 mg/ml solución inyectable y para perfusión (iopromida) (2026)– AEMPS, CIMA, nº registro 59614, revisión 08/2026, secciones 4.4 y 4.5
- FDA: Ultravist (iopromide) injection – Prescribing Information (2026)– FDA, DailyMed SPL, Bayer HealthCare, section 7.1
- AEMPS: Ficha técnica: Etoricoxib, Arcoxia 120 mg (nº registro 64930), sección 4.4 (2024)– AEMPS, CIMA, nº registro 64930 (Arcoxia 120 mg comprimidos recubiertos con película, Organon Salud), revisión 05/2024, secciones 4.3, 4.4, 4.5 y 4.8